The STING pathway - Roots Analysis
The STING pathway - Roots Analysis
Roots Analysis has done a detailed study on STING Pathway Targeting Therapeutics and Technologies, 2020-2030.” covering key aspects of the industry and identifying future growth opportunities.

To order this 310+page report, which features 150+ figures and 200+ tables, please visit this link


Key Market Insights

§  Many small / macro molecule-based STING pathway modulators are currentlybeing evaluated as monotherapies as well as in combination with other drugs

§ The pipeline features candidates targeting differenttherapeutic areas and designed for administration through a variety of routes;majority of such therapeutics are being developed as third-line and second-linetreatments

§ In recent years, several well funded start-ups have enteredthis field of research, and are gradually developing proprietary products basedon the STING pathway for the treatment of a variety of indications

§ In addition, a number of big pharmaceutical players havealso partnered with developers focused on STING targeting molecules in order toexpand their respective capabilities in this upcoming field of pharmacology

§ Published scientific literature indicates that bothindustry and academic players have made equal contributions to the innovationin this field; the major focus of such studies is presently on anti-cancertherapeutics

§ Several non-profit organizations have extended financialsupport to aid research efforts in this domain; the current focus appears to beon drug development and disease modelling studies

§ Foreseeing a lucrative future, private and public investorshave invested capital worth over USD 2.5 billion, across more than 80instances, in companies involved in STING pathway research

§ The rising interest is also reflected in recent partnershipactivity, involving the active participation of both international andindigenous companies; majority of the deals have been focused on noveltechnology platforms

§ Multiple companies are developing novel technologyplatforms for enhancing the research and development of STING pathway targetingtherapeutics

§ Technology developers are expected to continue relying onlicensing agreements involving different STING modulators as their primarysource of revenues in the foreseen future


For more information, please visit


Table of Contents


1.                PREFACE

1.1.              Scopeof the Report

1.2.              ResearchMethodology

1.3.              KeyQuestions Answered

1.4.              ChapterOutlines


2.                EXECUTIVESUMMARY


3.                INTRODUCTION

3.1.              Stimulator of Interferon Genes(STING) Pathway

3.2.              STING Signaling

3.2.1.           Relevance in Cancer

3.2.2.           Relevance in Autoimmune Diseases

3.2.3.           Relevance in Antimicrobial HostDefense


3.3.              STING Pathway Modulators

3.3.1.           STING Agonists

3.3.2.           STING Antagonists

3.3.3.           STING Activating Drug DeliverySystems

3.3.4.           Indirect STING Activating Therapies

3.4.              Key Variants of STING

3.5.              Non-immunological Functions of theSTING Pathway

3.6.              Concluding Remarks



4.1.              ChapterOverview

4.2.              STINGPathway Targeting Therapeutics: Development Pipeline

4.2.1.           Analysisby Type of STING Modulator

4.2.2.           Analysisby Type of Molecule

4.2.3.           Analysisby Phase of Development

4.2.4.           Analysisby Therapeutic Area

4.2.5.           Analysisby Type of Therapy

4.2.6.           Analysisby Route of Administration

4.2.7.           Analysisby Line of Treatment


4.3.              STINGPathway Targeting Therapeutics: Developer Landscape

4.3.1.           Analysisby Year of Establishment

4.3.2.           Analysisby Company Size

4.3.3.           Analysisby Geography

4.3.4.           MostActive Players


4.4.              STINGPathway Targeting Therapeutics: List of Clinical Trials

4.4.1.           Analysisby Trial Recruitment Status

4.4.2.           Analysisby Study Design

4.4.3.           Analysisby Key Clinical Endpoints



5.1.              Chapter Overview

5.2.              STING Pathway Targeting Technologies:List of Technology Developers

5.2.1.           Analysis by Type of Modulator

5.2.2.           Analysis by Type of Molecule

5.2.3.           Analysis by Year of Establishment

5.2.4.           Analysis by Company Size

5.2.5.           Analysis by Geography


6.                COMPANY PROFILES

6.1.              Chapter Overview

6.2               STINGAgonist Developers

6.2.1.           AduroBiotech        CompanyOverview        FinancialInformation        ProductDescription: ADU-S100 (MIW815)        RecentDevelopments and Future Outlook


6.2.2.           Bristol-MyersSquibb        CompanyOverview        FinancialInformation        ProductDescription: BMS-986301        RecentDevelopments and Future Outlook


6.2.3.           Eisai        CompanyOverview        FinancialInformation        ProductDescription: E7766        RecentDevelopments and Future Outlook


6.2.4            GlaxoSmithKline        CompanyOverview        FinancialInformation        ProductDescription: GSK3745417        RecentDevelopments and Future Outlook


6.2.5.           ImmuneSensorTherapeutics        CompanyOverview        ProductDescription: IMSA101


6.2.6.           Merck        CompanyOverview        FinancialInformation        ProductDescription: MK-1454 and MK-2118        RecentDevelopments and Future Outlook


6.2.7.           Noxopharm        CompanyOverview        ProductDescription: NOX66        RecentDevelopments and Future Outlook


6.2.8.           SpringBank Pharmaceuticals        CompanyOverview        FinancialInformation        ProductDescription: SB 11285        RecentDevelopments and Future Outlook


6.2.9.           Synlogic        CompanyOverview        FinancialInformation        ProductDescription: SYNB1891        RecentDevelopments and Future Outlook


6.3.              STINGAntagonist Developers

6.3.1            AvammuneTherapeutics

6.3.2.           Curadev

6.3.3            ImmuneSensorTherapeutics

6.3.4.           NimbusTherapeutics

6.3.5.           Sirenas

6.3.6.           SpringBank Pharmaceuticals

6.3.7.           STINGINN

6.3.8.           STipeTherapeutics



7.1.              Chapter Overview

7.2.              Scope and Methodology

7.3.              STING Pathway Targeting Therapeutics:List of Academic Grants

7.3.1.           Analysis by Number of Grants

7.3.2.           Analysis by Amount Awarded

7.3.3.           Analysis by Funding Institute

7.3.4.           Analysis by Support Period

7.3.5.           Analysis by Funding Mechanism

7.3.6.           Analysis by Type of Grant Application

7.3.7.           Analysis by Grant Activity Code

7.3.8.           Analysis by Funding Institutes

7.3.9.           Analysis by Type of RecipientOrganization

7.3.10          Regional Distribution of GrantRecipients

7.3.11          Most Popular Recipient Organizations:Analysis by Number of Grants and Amount Invested

7.3.12.         Prominent Project Leaders: Analysis byNumber of Grants

7.3.13          Analysis by Support Year and AmountAwarded

7.3.14.         Analysis by Study Section

7.4.              Grant Attractiveness Analysis



8.1.              Chapter Overview

8.2.              Scope and Methodology

8.3.              Initiatives Undertaken by BigPharma Players

8.3.1.           Analysis by Portfolio Diversity

8.3.2.           Analysis by Type of Molecule

8.3.3.           Analysis by Phase of Development

8.3.4.           Analysis by Therapeutic Area

8.3.5.           Analysis by Type of Therapy

8.3.6.           Analysis by Route of Administration


8.4.              Benchmarking Big Pharma Players

8.4.1            Spider Web Analysis: AbbVie

8.4.2.           Spider Web Analysis: Bayer

8.4.3.           Spider Web Analysis: Bristol-MyersSquibb

8.4.4.           Spider Web Analysis: Celgene

8.4.5.           Spider Web Analysis: Eisai

8.4.6.           Spider Web Analysis: Eli Lily

8.4.7.           Spider Web Analysis: Genentech

8.4.8.           Spider Web Analysis: GlaxoSmithKline

8.4.9.           Spider Web Analysis: Merck

8.4.10.         Spider Web Analysis: Novartis

8.4.11.         Spider Web Analysis: Novo Nordisk

8.4.12.         Spider Web Analysis: Pfizer

8.4.13.         Spider Web Analysis: Roche

8.4.14.         Spider Web Analysis: TakedaPharmaceuticals


9                 START-UP HEALTH INDEXING

9.1.              Chapter Overview

9.2.              Scope and Methodology

9.3.              Benchmarking of Start-ups

9.3.1.           Analysis by Portfolio Diversity

9.3.2.           Analysis by Type of Molecule

9.3.3.           Analysis by Phase of Development

9.3.4            Analysis by Therapeutic Area

9.3.5.           Analysis by Funding Amount

9.3.6.           Analysis by Number of Investors

9.3.7.           Analysis by Type of Funding

9.3.8.           Analysis by Partnership Activity

9.3.9.           Analysis by Other Parameters

9.3.10.         Analysis by Location of Headquarters

9.3.11.         Start-up Health Indexing: RootsAnalysis Perspective


10                PUBLICATION ANALYSIS

10.1.            ChapterOverview

10.2.            Scopeand Methodology

10.3.            STINGPathway Targeting Therapeutics: Recent Publications

10.3.1.         Analysisby Type of Publication

10.3.2.         Analysisby Type of Publication and Year

10.3.3.         Analysisby Study Objective

10.3.4.         Analysisby Popular Keywords

10.3.5.         Analysisby Type of STING Modulator

10.3.6.         Analysisby Target Pathway

10.3.7.         Analysisby Therapeutic Area

10.3.8.         Analysisby Type of STING Modulator and Therapeutic Area

10.3.9          Analysis by Type of Publisher

10.3.10.       Leading Players: Analysis by Number ofPublications

10.3.11.       Leading Players: Geographical Analysis byNumber of Publications

10.3.12.       Analysisby First Author Organization

10.3.13.       KeyJournals: Analysis by Number of Publications



11.1.            Chapter Overview

11.2.            Partnership Models

11.3.            STING Pathway TargetingTherapeutics: Recent Partnerships

11.3.1.         Analysis by Year of Partnership

11.3.2.         Analysis by Type of Partnership

11.3.3          Analysis by Type of STING Modulator

11.3.4.         Analysis by Therapeutic Area

11.3.5.         Analysis by Technology Platform

11.3.6.         Most Active Players: Analysis by Numberof Partnerships


11.3.7.         Geographical Analysis       Most Active Players: Analysis by Numberof partnerships      Intercontinental and IntracontinentalAgreements



12.1.            ChapterOverview

12.2.            Typesof Funding

12.3.            STINGPathway Targeting Therapeutics: Recent Funding Instances

12.3.1.         Analysisby Number of Funding Instances

12.3.2.         Analysisby Amount Invested

12.3.3.         Analysisby Type of Funding

12.3.4.         Analysisby Type of STING Modulator

12.3.6.         Analysisby Therapeutic Area

12.3.6          Analysisby Amount Invested and Type of STING Technology Platform

12.3.7.         MostActive Players: Analysis by Number of Funding Instances

12.3.8.         MostActive Investors: Analysis by Number of Funding Instances

12.3.9.         GeographicalAnalysis by Amount Invested

12.4.            ConcludingRemarks



13.1.            Chapter Overview

13.2.            Key Assumptions and Forecast Methodology

13.3.            Global STING Pathway TargetingTechnologies Market, 2020-2030

13.3.1.         STING Pathway Targeting TechnologiesMarket by Upfront Payments, 2020-2030

13.3.2.         STING Pathway Targeting TechnologiesMarket by Milestone Payments, 2020-2030

13.3.3.         STING Pathway Targeting TechnologiesMarket: Distribution by Type of STING Modulator      STING Pathway Targeting TechnologiesMarket for Agonist, 2020-2030      STING Pathway Targeting TechnologiesMarket for Antagonist, 2020-2030


13.3.4.         STING Pathway Targeting TechnologiesMarket: Distribution by Therapeutic Area      STING Pathway Targeting TechnologiesMarket for Oncological Disorders, 2020-2030      STING Pathway Targeting TechnologiesMarket for Inflammatory Disorders, 2020-2030      STING Pathway Targeting TechnologiesMarket for Infectious Diseases, 2020-2030      STING Pathway Targeting TechnologiesMarket for Other Therapeutic Areas, 2020-2030


13.3.5.         STING Pathway Targeting TechnologiesMarket: Distribution by Route of Administration      STING Pathway Targeting TechnologiesMarket for Intratumoral Route, 2020-2030      STING Pathway Targeting TechnologiesMarket for Intravenous Route, 2020-2030      STING Pathway Targeting TechnologiesMarket for Oral Route, 2020-2030      STING Pathway Targeting TechnologiesMarket for Subcutaneous Route, 2020-2030      STING Pathway Targeting TechnologiesMarket for Other Routes, 2020-2030


13.3.6.         STING Pathway Targeting TechnologiesMarket: Distribution by Type of Molecule      STING Pathway Targeting TechnologiesMarket for Non-Nucleotide, 2020-2030      STING Pathway Targeting TechnologiesMarket for Cyclic Dinucleotide, 2020-2030      STING Pathway Targeting TechnologiesMarket for Live Biotherapeutics, 2020-2030      STING Pathway Targeting TechnologiesMarket for Oncolytic Viruses, 2020-2030      STING Pathway Targeting TechnologiesMarket for Synthetic Peptides, 2020-2030      STING Pathway Targeting Technologies Marketfor Other Molecules, 2020-2030


13.3.7.         STING Pathway Targeting TechnologiesMarket: Distribution by Geography      STING Pathway Targeting TechnologiesMarket in North America, 2020-2030      STING Pathway Targeting TechnologiesMarket in Europe, 2020-2030      STING Pathway Targeting TechnologiesMarket in Asia-Pacific, 2020-2030


14.               EXECUTIVEINSIGHTS


15.               CONCLUDING REMARKS

15.1.            Chapter Overview

15.2.            Key Takeaways


16.               APPENDIX1: TABULATED DATA




Contact Details

Gaurav Chaudhary

+1 (415) 800 3415